Research programme: psychiatric and neurological disorders therapies - Evotec SE
Alternative Names: Psychiatric and neurological disorders therapies research programme - Evotec SELatest Information Update: 07 Oct 2019
At a glance
- Originator Evotec AG
- Developer Evotec SE
- Class
- Mechanism of Action Orexin receptor type 2 modulators; Phosphodiesterase 10A modulators; Serine racemase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Insomnia; Neurodegenerative disorders; Schizophrenia
- Discontinued Substance-related disorders
Most Recent Events
- 02 Apr 2014 No development reported - Preclinical for Insomnia in Germany (unspecified route)
- 02 Apr 2014 No development reported - Preclinical for Neurodegenerative disorders in Germany (unspecified route)
- 02 Apr 2014 No development reported - Preclinical for Schizophrenia in Germany (unspecified route)